TY - JOUR T1 - Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans JF - Anticancer Research JO - Anticancer Res SP - 2563 LP - 2568 VL - 29 IS - 7 AU - J. MONTEIL AU - N. MAHMOUDI AU - S. LEOBON AU - P.Y. ROUDAUT AU - A. EL BADAOUI AU - S. VERBEKE AU - L. VENAT-BOUVET AU - J. MARTIN AU - V. LE BRUN-LY AU - S. LAVAU-DENES AU - A. MAUBON AU - P. BOUILLET AU - M. POUQUET AU - J.C. VANDROUX AU - N. TUBIANA-MATHIEU Y1 - 2009/07/01 UR - http://ar.iiarjournals.org/content/29/7/2563.abstract N2 - Background: [18F]-fluorodeoxyglucose with positron-emission tomography (PET) and computed tomography (CT) scans were used to assess morphological and metabolic tumour response after chemotherapy in metastatic colorectal cancer. Patients and Methods: Twenty-five patients were evaluated after 4 courses of chemotherapy (±target therapy), and among them 20 patients after 2 courses. Response Evaluation Criteria In Solid Tumors (RECIST) and European Organisazion for Research and Treatment of Cancer (EORTC) criteria were used to evaluate CT and PET respectively. Results: Discrepancies between the two procedures were noted after 4 courses of chemotherapy in patient-based analysis. Two morphologically complete responses (CR) were correlated with metabolic response. Seven morphological partial responses (PR) were evaluated as 3 metabolic PR, 2 CR and 1 progressive disease (PD). Seventeen cases of morphologically stable disease (SD) were evaluated as 3 metabolic CR, 13 PR and 1 PD. These discrepancies were confirmed in lesion-based analysis. Perfect concordance was noted between metabolic responses obtained after 2 and 4 cycles. Conclusion: Morphological and metabolic imaging does not permit concordant therapeutic assessment in metastatic colorectal cancer. ER -